What Integrity Bio does

Integrity Bio is a privately held US biopharmaceutical services company headquartered in Camarillo, California, founded in 2003. The firm positions itself as a leader in protein formulation development, operating in a narrow specialty niche within the broader contract development and manufacturing (CDMO) services landscape. With 101–250 employees, Integrity Bio is mid-sized relative to large integrated CDMOs and competes on scientific depth in protein formulation rather than on end-to-end platform breadth.

The company's core offering centers on protein formulation development services for biopharma clients, a discipline that requires specialized expertise in protein stability, characterization, and delivery. Leadership comprises Michael Reilly as Chief Executive Officer and Byeong Chang as Founder and Chief Scientific Officer, indicating a founder-led scientific governance model with the founder retained in a senior technical role—an arrangement typical of specialist services firms that compete on accumulated technical know-how. The company is privately held with no public listing, no disclosed parent company, and no recorded subsidiaries in the provided data.

The business model follows a professional services / contract services pattern standard to biopharma formulation providers: revenue is generated through project-based formulation development engagements with biotech and pharmaceutical clients. The company maintains a single disclosed site in Camarillo and does not advertise a multi-region facility footprint. No customer logos, pricing model, funding history, M&A activity, or product launches are disclosed in the available data, which limits visibility into revenue mechanics, customer mix, and capital structure. The current data set suggests an established, specialist services firm with stable leadership and a defensible technical niche, but the absence of disclosed financials or strategic activity means any growth or expansion assessment is necessarily constrained.

Name

Integrity Bio

Legal name

Curia Global, Inc.

Website

https://integritybio.com

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

101–250 employees

Short description

Integrity Bio is a privately held Camarillo, California-based biopharmaceutical services firm founded in 2003, specializing in protein formulation development for biotech and pharma clients, with 101–250 employees and founder-led scientific leadership.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Formulation Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Bioprocess Consumables & Reagents (resins, membranes, media components, buffers) (HLAAAJAI)

akta.pro secondary industries

Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers) (HLAGAIAG), Process Analytical Technology (PAT) & In-Line/At-Line Analytics (spectroscopy, sensors, monitoring) (HLAAAJAD)

Keywords

• Protein formulation development
• Biopharmaceutical contract services
• Therapeutic protein services
• Formulation development services
• Biologics formulation services

Headquarters

HQ city

Camarillo

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

1. Contract Development and Manufacturing Services: Curia generates revenue through providing integrated CDMO services across drug discovery, development, and manufacturing. Services are contracted on a project basis with clients ranging from early-stage biotech to large pharmaceutical companies. Revenue is derived from service fees, manufacturing fees, and potentially milestone payments.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Integrity Bio is a privately held protein formulation development company that provides specialized contract services to biopharmaceutical clients. Founded in 2003 and based in Camarillo, California, the company focuses on developing formulations for protein-based therapeutics, supporting drug development and manufacturing pipelines for its biopharma customers.

Product overview

Curia Global is a global Contract Development and Manufacturing Organization (CDMO) offering integrated pharmaceutical services across four main verticals: Small Molecule (discovery through manufacturing), Generic APIs, Biologics (discovery through GMP), and Sterile Drug Product. The company operates 20+ facilities across North America, Europe, and India with 3,000+ professionals. Services include specialized offerings such as mRNA/LNP formulation, high potency API manufacturing, fermentation, flow chemistry, and analytical testing. The Fine Chemicals product line includes specialty reagents like T3P and Gemagique polymers.

Differentiator

Problem solved

Functional benefit

Brands

• Gemagique® AMPS Polymers: Fine chemical polymer product line
• T3P® Reagent

Products and services

• Protein Formulation Development Contract service offering focused on protein formulation development for biopharmaceutical clients developing protein-based therapeutics. The service provides specialized scientific expertise in protein formulation design, optimization, and development to support drug development programs.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Scale indicators4 records

Broad incumbents

• WuXi Biologics: Global biologics CDMO offering end-to-end services from cell line development through commercial GMP manufacturing, formulation, and fill-finish for monoclonal antibodies and recombinant proteins. A broad incumbent that competes with Integrity Bio for protein formulation and biologics manufacturing programs.
• Lonza Group: One of the world's largest CDMOs with deep biologics capabilities spanning mammalian and microbial process development, GMP manufacturing, formulation, and fill-finish. Relevant broad incumbent competing for protein formulation programs across all stages of development and serving many of the same biopharma clients.
• Catalent: Large global CDMO with biologics, cell and gene therapy, and sterile fill-finish capabilities. Comparable as a broad incumbent that bundles protein formulation and drug product services for biopharma customers, often competing for the same formulation programs as Integrity Bio.
• Curia Global: Integrity Bio's parent company and the most direct strategic counterparty. Curia is a global CDMO with 20+ facilities, 3,000+ professionals, and an integrated platform spanning small molecule, generic APIs, biologics, and sterile drug product. It is highly comparable because Integrity Bio's protein formulation work sits inside Curia's broader biologics offering and benefits from shared capabilities (mammalian GMP, mRNA/LNP, analytical services).
• Samsung Biologics: Large-scale biologics CDMO with extensive mammalian cell culture GMP capacity, process development, and aseptic fill-finish. Comparable as a broad incumbent in protein biologics manufacturing and formulation, particularly for late-stage and commercial programs.

Direct peers

• Vibalogics: Specialized CDMO focused on complex biologics including viral vaccines, gene therapies, and protein-based therapeutics, with process development, GMP manufacturing, and fill-finish. Comparable as a similarly-sized, specialized biologics CDMO competing for similar protein and complex biologic formulation programs.
• Abzena: Biologics-focused CDMO offering antibody/protein discovery, cell line development, process development, analytical, and bioconjugation services. Comparable to Integrity Bio as a biologics specialty CDMO with development-stage service offerings in protein therapeutics.
• AGC Biologics: Global biologics CDMO offering mammalian cell line development, process development, GMP manufacturing, and formulation/fill-finish for proteins, antibodies, and other biologics. Directly comparable to Integrity Bio's protein formulation and bioprocess development focus, serving overlapping biopharma clients.
• Cytovance Biologics: U.S.-based biologics CDMO (part of the Hepalink group) providing microbial and mammalian process development, GMP manufacturing, and aseptic fill-finish for proteins and other biologics. Closely comparable in scale and service scope to Integrity Bio, with overlapping protein formulation and bioprocess offerings.

Emerging players

• Bora Biologics: Growing biologics CDMO with mammalian cell culture, process development, GMP manufacturing, and fill-finish capabilities, expanding internationally from its Taiwan base. Comparable as an emerging biologics-focused CDMO competing in protein formulation and bioprocess development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/integrity-bio
• Xx.com/ProteinForm

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Integrity Bio